S&P 500   3,921.10 (-0.07%)
DOW   31,300.33 (-0.60%)
QQQ   292.02 (+0.30%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
S&P 500   3,921.10 (-0.07%)
DOW   31,300.33 (-0.60%)
QQQ   292.02 (+0.30%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
S&P 500   3,921.10 (-0.07%)
DOW   31,300.33 (-0.60%)
QQQ   292.02 (+0.30%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
S&P 500   3,921.10 (-0.07%)
DOW   31,300.33 (-0.60%)
QQQ   292.02 (+0.30%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
NASDAQ:ALLK

Allakos (ALLK) Stock Forecast, Price & News

$2.91
-0.05 (-1.69%)
(As of 05/19/2022 10:09 AM ET)
Add
Compare
Today's Range
$2.91
$3.05
50-Day Range
$2.85
$6.19
52-Week Range
$2.77
$11.73
Volume
3,517 shs
Average Volume
978,199 shs
Market Capitalization
$159.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.96
30 days | 90 days | 365 days | Advanced Chart
Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Allakos logo

About Allakos

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Headlines

What 4 Analyst Ratings Have To Say About Allakos
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.74 per share

Profitability

Net Income
$-269.86 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
36,564,000
Market Cap
$159.41 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/06/2022
Today
5/19/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

256th out of 1,418 stocks

Pharmaceutical Preparations Industry

98th out of 677 stocks

Analyst Opinion: 3.1Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -













Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Allakos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View analyst ratings for Allakos
or view top-rated stocks.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Allakos
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings results on Friday, May, 6th. The company reported ($3.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by $1.65.
View Allakos' earnings history
.

What price target have analysts set for ALLK?

10 brokers have issued 12 month target prices for Allakos' stock. Their forecasts range from $13.00 to $155.00. On average, they anticipate Allakos' stock price to reach $68.42 in the next twelve months. This suggests a possible upside of 2,251.3% from the stock's current price.
View analysts' price targets for Allakos
or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?
Allakos' management team includes the following people:
  • Dr. Robert Alexander Ph.D., CEO & Director (Age 52, Pay $1.39M)
  • Dr. Adam L. Tomasi Ph.D., Pres & COO (Age 52, Pay $1.06M)
  • Mr. Baird Radford III, Chief Financial Officer
  • Mr. Mark Asbury J.D., Exec. Officer (Age 59, Pay $701.69k)
  • Dr. Ruby Casareno Ph.D., Sr. VP of Technical Operations
  • Meg Fitzgerald, Sr. VP, Gen. Counsel, Sec. and Chief Compliance Officer
  • Dr. Sally D. Bolmer, Sr. VP of Regulatory Affairs & Drug Devel.
  • Dr. Henrik Sandvad Rasmussen, Strategic Advisor (Age 63)
  • Dr. Craig Paterson M.D., Chief Medical Officer
  • Brad Youngblood, Head of Research
What other stocks do shareholders of Allakos own?
When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.32%), Vanguard Group Inc. (4.84%), Goldman Sachs Group Inc. (1.84%), State Street Corp (1.43%), PDT Partners LLC (1.21%) and Clearline Capital LP (0.98%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends for Allakos
.

Which major investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Simplex Trading LLC, Group One Trading L.P., Citigroup Inc., RBF Capital LLC, Cutler Group LP, and Engineers Gate Manager LP. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Henrik S Md Rasmussen, Robert Alexander, and Steven P James.
View insider buying and selling activity for Allakos
or view top insider-selling stocks.

Which major investors are buying Allakos stock?

ALLK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., PDT Partners LLC, Clearline Capital LP, JPMorgan Chase & Co., Acadian Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Allakos
or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $2.91.

How much money does Allakos make?

Allakos has a market capitalization of $159.41 million. The company earns $-269.86 million in net income (profit) each year or ($7.56) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 192 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 597-5002 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.